Efficacy and Safety of EGFR Inhibitors and Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: a Meta-Analysis

EGFR-tyrosine kinase inhibitors combined with (chemo)radiotherapy are tolerable and the clinical benefit is promising, especially in patients with EGFR-sensitive mutations.